SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Schedule of Revenue by Payor Class

Revenue by payor class as a percentage of total net service revenue is as follows:

	For the Three-Month Periods Ended June 30,				For the Six-Month Periods Ended June 30,
	2021		2020		2021		2020
Home Health:
Medicare	42	%	40	%	42	%	41	%
Non-Medicare - Episodic-based	8	%	6	%	8	%	6	%
Non-Medicare - Non-episodic based	12	%	14	%	12	%	14	%
Hospice (1):
Medicare	33	%	34	%	33	%	33	%
Non-Medicare	2	%	2	%	2	%	2	%
Personal Care	3	%	4	%	3	%	4	%
	100	%	100	%	100	%	100	%
(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):

	As of June 30, 2021		As of December 31, 2020
Cash and cash equivalents	$	91.6	$	81.8
Restricted cash	1.0		1.5
Cash, cash equivalents and restricted cash	$	92.6	$	83.3

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):

	Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of June 30, 2021		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	189.7	$	—	$	191.7	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):

	For the Three- Month Periods Ended June 30,		For the Six- Month Periods Ended June 30,
	2021	2020	2021	2020
Weighted average number of shares outstanding - basic	32,588	32,412	32,684	32,371
Effect of dilutive securities:
Stock options	139	570	145	582
Non-vested stock and stock units	254	303	256	306
Weighted average number of shares outstanding - diluted	32,981	33,285	33,085	33,259
Anti-dilutive securities	71	14	58	21